Policy

About PMC Public Policy

Scientific advancements in personalized medicine have given life to a body of knowledge that can improve patient outcomes, reduce the cost of health care and eliminate inefficiencies that now plague our health care system. But in order to ensure that clinicians, researchers and patients realize these benefits, this new way of conceptualizing medicine must be nurtured and applied within a carefully constructed regulatory and reimbursement environment. In collaboration with our members, thought leaders, and other stakeholders in personalized medicine, PMC facilitates the development of public policies that allow for the timely and effective application and advancement of personalized medicine and advocates for those policies. Though our public policy work, PMC seeks to:

1. Encourage innovation by supporting health information technology, evidence generation and patient engagement with the goals of increasing system efficiency and maximizing value for patients
   
2. Recognize the importance of reimbursement for diagnostics and therapeutics that serve as the foundation of personalized medicine by working to alleviate confusion and contention between innovators and payers
   
3. Clarify future requirements for developing and testing personalized medicine products, thereby establishing a business model for use by the pharmaceutical and diagnostic industries
   

The PMC Public Policy Committee

The work described above is completed during PMC Public Policy Committee meetings and the deliberations of that group.  During meetings of the public policy committee, members develop specific policy positions and the strategies by which these positions are communicated to target audiences, which often include branches of the federal government and other non-governmental agencies. J. Brian Munroe of Endo Pharmaceuticals chairs the 2014 committee.”